54
Utilidad de la glucosa 1-hora post-carga para la evaluación del riesgo de diabetes y sus complicaciones asociadas
resistance and hyperinsulinemia: is hyperinsulinemia the 28. Gudipaty L, Rosenfeld NK, Fuller CS, Gallop R, Schutta MH,
cart or the horse? Diabetes Care. 2008;31 Suppl 2: S262-8.
5. Reaven GM. The insulin resistance syndrome: definition
and dietary approaches to treatment. Annu Rev Nutr. 2005;
5:391-406.
6. Viitasalo A, Lakka TA, Laaksonen DE, Savonen K, Lakka HM,
Rickels MR. Effect of exenatide, sitagliptin, or glimepiride
on beta-cell secretory capacity in early type 2 diabetes.
Diabetes Care. 2014;37(9):2451-8.
1
2
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher
DF, Turner RC. Homeostasis model assessment: insulin
resistance and beta-cell function from fasting plasma
glucose and insulin concentrations in man. Diabetologia.
1985;28(7):412-9.
1
Hassinen M, et al. Validation of metabolic syndrome score by
confirmatory factor analysis in children and adults and pre-
diction of cardiometabolic outcomes in adults. Diabetologia.
2
014;24.
30. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan
G, et al. Quantitative insulin sensitivity check index: a simple,
accurate method for assessing insulin sensitivity in hu-
mans. J Clin Endocrinol Metab. 2000;85(7):2402-10.
31. Ballerini M, Bergadá I, Rodríguez M, Keselman A, Bengolea V,
Pipman V, et al. Concentración de insulina e índices de insu-
linosensibilidad en niños y adolescentes sanos. Arch Argent
Pediatr. 2016; 114:329-36.
32. Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A,
Nakhjavani M, Rashidi A, et al. Optimal cut-off of homeosta-
sis model assessment of insulin resistance (HOMA-IR) for
the diagnosis of metabolic syndrome: third national survei-
llance of risk factors of non-communicable diseases in Iran
(SuRFNCD-2007). Nutr Metab (Lond). 2010;7:26.
1
7. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB, Sr., Wilson
PW. Insulin resistance, the metabolic syndrome, and inci-
dent cardiovascular events in the Framingham Offspring
Study. Diabetes. 2005;54(11):3252-7.
1
8. Howard G, O’Leary DH, Zaccaro D, Haffner S, Rewers M,
Hamman R, et al. Insulin sensitivity and atherosclero-
sis. The Insulin Resistance Atherosclerosis Study (IRAS)
Investigators. Circulation. 1996;15;93(10):1809-17.
9. Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM.
Insulin resistance and risk of incident cardiovascular
events in adults without diabetes: meta-analysis. PLoS One.
1
2012;7(12): e52036.
2
0. Czernichow S, Bruckert E, Bertrais S, Galan P, Hercberg S,
Oppert JM. Hypertriglyceridemic waist and 7.5-year prospec- 33. Matsuda M, DeFronzo RA. Insulin sensitivity indices
tive risk of cardiovascular disease in asymptomatic middle-
aged men. Int J Obes (Lond). 2007;31(5):791-6.
1. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of
obtained from oral glucose tolerance testing: compari-
son with the euglycemic insulin clamp. Diabetes Care.
1999;22(9):1462-70.
2
beta-cell dysfunction and insulin resistance to the patho- 34. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based
genesis of impaired glucose tolerance and impaired fasting
glucose. Diabetes Care. 2006;29(5):1130-9.
method for assessing insulin sensitivity from the oral gluco-
se tolerance test. Diabetes Care. 2001;24(3):539-48.
22. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. The na- 35. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Jarvinen
tural history of progression from normal glucose tolerance
to type 2 diabetes in the Baltimore Longitudinal Study of
Aging. Diabetes. 2003;52(6):1475-84.
H, Van Haeften T, et al. Use of the oral glucose tolerance test
to assess insulin release and insulin sensitivity. Diabetes
Care. 2000;23(3):295-301.
23. DECODE study group. Glucose tolerance and mortality: 36. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki
comparison of WHO and American Diabetes Association
diagnostic criteria. The DECODE study group. European
Diabetes Epidemiology Group. Diabetes Epidemiology:
EM, et al. Validation of the insulin sensitivity index (ISI
(0,120)): comparison with other measures. Diabetes Res
Clin Pract. 2000;47(3):177-84.
Collaborative analysis Of Diagnostic criteria in Europe. 37. Furugen M, Saitoh S, Ohnishi H, Akasaka H, Mitsumata K,
Lancet. 1999 ;21;354(9179):617-21.
4. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of
Chiba M, et al. Matsuda-DeFronzo insulin sensitivity in-
dex is a better predictor than HOMA-IR of hypertension in
Japanese: the Tanno-Sobetsu study. J Hum Hypertens.
2012;26(5):325-33.
2
cardiovascular risk in prediabetes: impaired glucose toleran-
ce and impaired fasting glucose. Am J Cardiol. 2011;2;108(3
Suppl):3B-24B.
38. Andreozzi F, Gastaldelli A, Mannino GC, Sciacqua A, Succurro
E, Arturi F, et al. Increased carotid intima-media thickness in
the physiologic range is associated with impaired postpran-
dial glucose metabolism, insulin resistance and beta cell
dysfunction. Atherosclerosis. 2013;229(2):277-81.
39. Mulvey CK, McNeill AM, Girman CJ, Churchill TW, Terembula
K, Ferguson JF, et al. Differential associations of oral glucose
tolerance test-derived measures of insulin sensitivity and
pancreatic beta-cell function with coronary artery calcifica-
tion and microalbuminuria in type 2 diabetes. Diabetes Care.
2014;37(1):124-33.
2
5. DeFronzo RA, Banerji MA, Bray GA, Buchanan TA, Clement
S, Henry RR, et al. Determinants of glucose tolerance in
impaired glucose tolerance at baseline in the Actos Now
for Prevention of Diabetes (ACT NOW) study. Diabetologia.
2010;53(3):435-45.
26. Defronzo RA. Banting Lecture. From the triumvirate to the
ominous octet: a new paradigm for the treatment of type 2
diabetes mellitus. Diabetes. 2009;58(4):773-95.
2
7. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a
method for quantifying insulin secretion and resistance. Am
J Physiol. 1979;237(3):E214-23.
40. Szosland K, Lewinski A. In quest for method of insulin re-
ByPC 2018;82(1):46-57.